| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | Oct 2, 2025 | VYNE Therapeutics Inc. | CEO | Sell | 47.5 | -12,676 | -2.87% | ✗ | $4.2K |
| Jun 30, 2025 | Jul 2, 2025 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -12,676 | -2.79% | ✗ | $20.9K |
| Mar 31, 2025 | Apr 2, 2025 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -30,498 | -6.41% | ✗ | $48.2K |
| Dec 31, 2024 | Jan 2, 2025 | VYNE Therapeutics Inc. | CEO | Sell | 42.5 | -24,536 | -4.90% | ✗ | $82.2K |
| Sep 30, 2024 | Oct 2, 2024 | VYNE Therapeutics Inc. | CEO | Sell | 52.5 | -685 | -0.14% | ✗ | $1.3K |
| Jul 1, 2024 | Jul 3, 2024 | VYNE Therapeutics Inc. | CEO | Sell | 52.5 | -935 | -0.19% | ✗ | $1.8K |
| Apr 1, 2024 | Apr 3, 2024 | VYNE Therapeutics Inc. | CEO | Sell | 52.5 | -1,004 | -0.20% | ✗ | $3.1K |
| Jan 1, 2024 | Jan 3, 2024 | VYNE Therapeutics Inc. | CEO | Sell | 90.0 | +223,996 | 82.60% | ✗ | $2.3K |
| Oct 2, 2023 | Oct 4, 2023 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -8,549 | -16.30% | ✗ | $32.7K |
| Jun 30, 2023 | Jul 5, 2023 | VYNE Therapeutics Inc. | CEO | Sell | 47.5 | -981 | -1.84% | ✗ | $4K |
| Mar 31, 2023 | Apr 4, 2023 | VYNE Therapeutics Inc. | CEO | Sell | 47.5 | -2,734 | -5.12% | ✗ | $8.4K |
| Dec 31, 2022 | Jan 4, 2023 | VYNE Therapeutics Inc. | CEO | Sell | 50.0 | -10,685 | -0.99% | ✗ | $1.6K |
| Sep 30, 2022 | Oct 4, 2022 | VYNE Therapeutics Inc. | CEO | Sell | 47.5 | -10,683 | -1.02% | ✗ | $2.4K |
| Jun 30, 2022 | Jul 5, 2022 | VYNE Therapeutics Inc. | CEO | Sell | 47.5 | -10,683 | -1.01% | ✗ | $4.2K |
| Mar 31, 2022 | Apr 4, 2022 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -23,186 | -2.16% | ✗ | $15.1K |
| Dec 31, 2021 | Jan 4, 2022 | VYNE Therapeutics Inc. | CEO | Sell | 50.0 | -6,887 | -0.90% | ✗ | $7K |
| Sep 30, 2021 | Oct 1, 2021 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -13,096 | -1.69% | ✗ | $18.2K |
| Jun 30, 2021 | Jul 2, 2021 | VYNE Therapeutics Inc. | CEO | Sell | 42.5 | -18,859 | -3.97% | ✗ | $66.2K |
| Mar 31, 2021 | Apr 2, 2021 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -6,316 | -1.32% | ✗ | $43.2K |
| Dec 31, 2020 | Jan 5, 2021 | VYNE Therapeutics Inc. | CEO | Sell | 48.8 | -9,656 | -0.73% | ✗ | $15.3K |
| Sep 30, 2020 | Oct 2, 2020 | VYNE Therapeutics Inc. | CEO | Sell | 51.3 | -6,239 | -0.47% | ✗ | $10.4K |
| Sep 8, 2020 | Sep 8, 2020 | VYNE Therapeutics Inc. | CEO | Buy | 90.0 | +75,000 | 6.04% | ✗ | $103.6K |
| Jun 30, 2020 | Jul 2, 2020 | VYNE Therapeutics Inc. | CEO | Sell | 48.8 | -6,239 | -0.50% | ✗ | $10.8K |
| Apr 3, 2020 | Apr 7, 2020 | VYNE Therapeutics Inc. | CEO | Sell | 91.3 | +379,717 | 202.52% | ✗ | $16.5K |
| Mar 31, 2020 | Apr 2, 2020 | VYNE Therapeutics Inc. | CEO | Sell | 46.3 | -4,456 | -2.32% | ✗ | $11.9K |